• August 2021

    Sigmapharm initiates a Voluntary Recall at the Retail Level for its drug product, Sodium Phenylbutyrate Powder, 250 Grams. This recall has been initiated due to the out of-specification (OOS) impurity results obtained during routine quality testing of a stability sample for one lot of Sodium Phenylbutyrate Powder, 250 Grams. This recall is being extended to all other potentially impacted lots as mentioned in the attached Recall letters dated August 13, 2021 and September 21, 2021.

  • July 2021

    Sigmapharm relaunches its generic Ultramicrosize Griseofulvin Tablets, USP 125 mg and 250 mg, exclusively under its own label.

  • June 2021

    Sigmapharm relaunches its generic Amiloride Hydrochloride Tablets, USP 5 mg, exclusively under its own label.

  • June 2021

    Ms. Mary E. Kohart, Esq., who had joined the company in October 2020 as its Vice President of the Legal Affairs Department, has now also become the General Counsel of Sigmapharm Laboratories.  Effective today, Mary will be in charge of all legal matters of the company, including but not limited to Paragraph-IV patent challenges and commercial litigation, contractual matters and strategic negotiations.  A short biographical note of Mary’s has now been posted in the MANAGEMENT section of our website.  

    Please note that all outside legal counsel, law firms, vendors, customers and other companies wishing to communicate with Sigmapharm Laboratories for any legal, litigation or contractual matters are now directed to contact only Ms. Mary Kohart at:

    Mary E. Kohart, Esq.
    General Counsel and Vice President, Legal Affairs
    Sigmapharm Laboratories, LLC

    3375 Progress Drive
    Bensalem, PA 19020
    Tel.:    (215) 352-6649
    Email:    MKohart@sigmapharm.com